Holen Sie sich die Stockscreener-App
0.8343
0.28%
0.0023
Handel nachbörslich:
.86
0.0257
+3.08%
Predictive Oncology Inc Aktie (POAI) Neueste Nachrichten
Predictive Oncology Inc. (NASDAQ:POAI) Short Interest Up 50.6% in May - Defense World
Labcorp (LH) Gains Exclusive 3D Liver Models from Predictive Onc - GuruFocus
Predictive Oncology develops liver toxicity models for Labcor By Investing.com - Investing.com South Africa
Predictive Oncology Develops 3D Liver Toxicity Models for Labcorp - MarketScreener
Predictive Oncology Inc. Develops Functional 3D Organoid Models Exclusively for Labcorp - MarketScreener
Predictive Oncology develops liver toxicity models for Labcor - Investing.com Australia
Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp - The Manila Times
Predictive Oncology Inc. Develops Exclusive 3D Organoid Models for Labcorp to Enhance Drug Discovery and Safety Evaluation - Nasdaq
Revolutionary 3D Organoid Models: How Predictive Oncology's Exclusive Labcorp Deal Transforms Drug Testing - Stock Titan
Predictive Oncology Faces Nasdaq Delisting Notice - TipRanks
Predictive Oncology (NASDAQ:POAI) Stock Price Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Major AI Breakthrough in Cancer Research: Leading Pharma Companies Unite in Revolutionary Oncology Initiative - Stock Titan
SEC Form 424B5 filed by Predictive Oncology Inc. - Quantisnow
'It's not something you choose to do, it's something you have to do': CEO & artist shares story - WTAE
Predictive Oncology (NASDAQ:POAI) Stock Crosses Below 200 Day Moving Average – Time to Sell? - Defense World
Court Denies Renovaro Motion for an Expedited Trial in July - GlobeNewswire
Predictive Oncology says court denies Renovaro motion for expedited trial - TipRanks
Predictive Oncology to defend against Renovaro’s claims in court By Investing.com - Investing.com Canada
Predictive Oncology (POAI) Addresses Legal Dispute with Renovaro - GuruFocus
Predictive Oncology to defend against Renovaro’s claims in court - Investing.com Australia
Court Denies Renovaro Motion for an Expedited Trial in July | POAI Stock News - GuruFocus
Delaware Court Rejects Renovaro's Rush to Trial Against Predictive Oncology, Cites Critical Delays - Stock Titan
Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger - MSN
Predictive Oncology Stock Hits 1-Month Low Amid Renovaro Legal Clash, But Retail Leans Bullish By Stocktwits - Investing.com India
UPDATERenovaro Inc. Announces Expedited Trial for 2025 Lawsui - GuruFocus
Predictive Oncology (POAI) Advances AI-Driven Cancer Drug Discov - GuruFocus
Renovaro Sues Predictive Oncology (POAI) Over Merger Agreement D - GuruFocus
Renovaro Gets Expedited Trial in Predictive Oncology Merger Dispute - marketscreener.com
Renovaro Sues Predictive Oncology (POAI) Over Merger Agreement Dispute | POAI Stock News - GuruFocus
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology - The Manila Times
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology | RENB Stock News - GuruFocus
Renovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger Agreement - Nasdaq
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to - GlobeNewswire
Court Fast-Tracks Renovaro's Lawsuit to Force Predictive Oncology Merger After 50% Stock Jump Drama - Stock Titan
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition | POAI Stock News - GuruFocus
Predictive Oncology harnesses AI for drug discovery - Investing.com
Predictive Oncology moves to leverage biobank using AI - TipRanks
Predictive Oncology harnesses AI for drug discovery By Investing.com - Investing.com Nigeria
Predictive Oncology Inc. Advances AI-Driven Drug Discovery with Extensive Biobank of Tumor Samples - Nasdaq
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition - GlobeNewswire
Major AI Breakthrough: How 150,000 Live Tumor Samples Are Revolutionizing Cancer Drug Discovery - Stock Titan
Predictive Oncology issued shareholder letter - TipRanks
Predictive Oncology (POAI) Showcases Recent Achievements and Future Plans | POAI Stock News - GuruFocus
Predictive Oncology Inc. Issues Shareholder Letter Titled, - GuruFocus
Predictive Oncology Expands AI-Driven Platform to Include Biomarker Discovery and Drug Repurposing for Precision Oncology - Nasdaq
Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: ... - Bluefield Daily Telegraph
0.46%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):